Prolynx
- Headquarters
- San Francisco, California
- Employees
- 1–10
- Founded
- 2010
- Business Model
- B2G
- Website
- prolynxinc.com
- Total Funding
- $70.0M
- Last Round
- $70.0M Series ANov 2025
About
ProLynx is a biotechnology company developing ultra-long-acting therapeutics for obesity and related metabolic diseases. Founded in 2010 by chemists from UCSF, the company's proprietary half-life extension platform enables once-monthly and once-quarterly dosing regimens, improving treatment adherence and tolerability compared to existing obesity drugs. Based in San Francisco, ProLynx raised a $70 million Series A in December 2025.
Sign up to view funding chart
Create a free account to see funding visualizations and detailed round data.
Create Free AccountFunding History
Sign up to view funding details
Create a free account to see full funding history, valuations, and investor participation.
Create Free Account